Trial · NCT02609932
Effect of IFN-γ on Innate Immune Cells
NCT02609932, Phase 1, Completed, University of Colorado, Denver
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effect of IFN-γ on Innate Immune Cells. Trials, record NCT02609932. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02609932
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effect of IFN-γ on Innate Immune Cells
- NCT number
- NCT02609932
- Status
- Completed
- Phases
- Phase 1
- Enrollment
- 20 participants, actual
- Lead sponsor
- University of Colorado, Denver
- Conditions
- Chronic Granulomatous Disease
- Interventions
- Administration of drug (Interferon-gamma 1-b) subcutaneously
- First posted
- 2015-11-20
- Last updated
- 2019-02-15
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Neutrophil Nox2 activity. | Determine the change in Nox2 activity at baseline compared to results for 8,24,48,72,96 hours after each IFN dose for the SD cohort. | Nox2 activity will be measured by DHR oxidation or Sod inhibitable cytochrome c reduction. |
| Primary | Change in Plasma IL-10 and Neuropterin concentration. | Determine the change in IL-10 and neuropterin concentration at baseline compared to 4, 8, 12, 24, 36, 48, 72, and 96 hours after each IFN dose, SD cohort. | IL-10nd Neuropterin will be measured by ELISA. |
| Primary | Change in Neutrophil Gene Expression Analysis. | Determine the change in gene expression at baseline compared to 4, 8, 12, 24, 36, 48, 72, and 96 hours after each IFN dose, SD cohort. | RNA will be extracted and gene expression will be determined by Affimetrix Gene Chip assay. |
| Primary | Change in IFN concentration and detection of anti-IFN antibody | Determine the change in IFN level at baseline compared to 4, 8, 12, and 24 hours after administration of each dose of IFN-gamma in the SD cohort. Determine the change in IFN antibody at baseline compared to day 7-10 and day 30 after IFN | IFN levels and anti-drug antibody will be completed by standard assays. |
| Secondary | Change in Neutrophil Function studies. | Determine the change in neutrophil function at baseline compared to results on Day 8 after the 4th dose of IFN. | Neutrophil chemotaxis, bactericidal activity,ingestion, degranulation, f-Actin expression, CD11b/18 expression, Nox2 activity to a variety of agonists. |
| Secondary | Change in Anti-IFN antibody. | Determine the change in IFN antibody at baseline compared to results for 7-10 da. and 30 da. after IFN. | Anti-drug antibody to be determined by standard assay. |
| Secondary | Change in Monocyte function studies. | Determine the change in monocyte function at baseline compared to results on Day 8 after the 4th dose of IFN. | Monocyte chemotaxis, bactericidal activity,ingestion, Expression of monocyte specific surface determinants, CD11b/18 expression, Nox2 activity to a variety of agonists, cell content of specific proteins, and antibody dependent cellular cytotoxicity. |
| Secondary | Change in Neutrophil and Monocyte Gene Expression Analysis. | Determine the change in monocyte function at baseline compared to results on Day 8 after the 4th dose of IFN. | RNA will be extracted and gene expression will be determined by Affimetrix Gene Chip assay. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| UL1TR001082 | Colorado Clinical and Translational Sciences Institute | SOKOL, RONALD J. | UNIVERSITY OF COLORADO DENVER | NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES | 2013 to 2017 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02609932
GET https://conductscience.org/api/trials/v1/NCT02609932/registered